^
Association details:
| Biomarker: | MYCN amplification |
|---|---|
| Cancer: | Neuroblastoma |
| Drug Class: | DHODH inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
Published date:
08/30/2021
Excerpt:
Genetic and pharmacological inhibition of DHODH suppresses the proliferation and tumorigenicity of MYCN-amplified neuroblastoma cell lines....Importantly, dipyridamole synergizes with DHODH inhibition to suppress neuroblastoma growth in animal models. These findings suggest that a combination of targeting DHODH and nucleoside transport is a promising strategy to overcome intrinsic resistance to DHODH-based cancer therapeutics.
DOI:
10.1038/s41419-021-04120-w
Source:
Title:
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
Published date:
08/30/2021
Excerpt:
Genetic and pharmacological inhibition of DHODH suppresses the proliferation and tumorigenicity of MYCN-amplified neuroblastoma cell lines....Importantly, dipyridamole synergizes with DHODH inhibition to suppress neuroblastoma growth in animal models. These findings suggest that a combination of targeting DHODH and nucleoside transport is a promising strategy to overcome intrinsic resistance to DHODH-based cancer therapeutics.
DOI:
10.1038/s41419-021-04120-w
